136 related articles for article (PubMed ID: 35850113)
1. Myeloid Sarcoma of the Breast as Blast Phase of JAK2-Mutated (Val617Phe Exon 14p) Essential Thrombocythemia: A Case Report and a Systematic Literature Review.
Pace M; Guadagno E; Russo D; Gencarelli A; Carlea A; Di Spiezio A; Bertuzzi C; Mascolo M; Grimaldi F; Insabato L
Pathobiology; 2023; 90(2):123-130. PubMed ID: 35850113
[TBL] [Abstract][Full Text] [Related]
2. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
[TBL] [Abstract][Full Text] [Related]
3. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
4. Myeloid sarcoma with megakaryoblastic differentiation mimicking a sellar tumor.
Novello M; Coli A; Della Pepa GM; Martini M; Doglietto F; De Stefano V; Bellesi S; Pescarmona E; Lauriola L
Neuropathology; 2014 Apr; 34(2):179-84. PubMed ID: 24118374
[TBL] [Abstract][Full Text] [Related]
5. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
Yoshiki Y; Asai T; Ichikawa M; Hangaishi A; Ota S; Imai Y; Takahashi T; Kurokawa M
Intern Med; 2011; 50(21):2649-52. PubMed ID: 22041374
[TBL] [Abstract][Full Text] [Related]
6. Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.
Ding W; Li D; Zhuang C; Wei P; Mou W; Zhang L; Liang H; Liu Y
Medicine (Baltimore); 2018 Jul; 97(27):e11331. PubMed ID: 29979407
[TBL] [Abstract][Full Text] [Related]
7. The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.
Hsieh PP; Olsen RJ; O'Malley DP; Konoplev SN; Hussong JW; Dunphy CH; Perkins SL; Cheng L; Lin P; Chang CC
Mod Pathol; 2007 Sep; 20(9):929-35. PubMed ID: 17643100
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
9. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
10. Postsplenectomy sclerosing extramedullary hematopoietic tumor with unexpected good clinical evolution: morphologic, immunohistochemical, and molecular analysis of one case and review of the literature.
Gualco G; Ojopi EB; Chioato L; Cordeiro DL; Negretti F; Bacchi CE
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):291-5. PubMed ID: 20042850
[TBL] [Abstract][Full Text] [Related]
11. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
12. Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.
Lapecorella M; Tabilio A; Lucchesi A; Napolitano M; Colagrande M; Di Ianni M; Mariani G
Blood Coagul Fibrinolysis; 2008 Jul; 19(5):453-7. PubMed ID: 18600099
[TBL] [Abstract][Full Text] [Related]
13. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
Wang J; Zhang B; Chen B; Zhou RF; Zhang QG; Li J; Yang YG; Zhou M; Shao XY; Xu Y; Xu XH; Ouyang J; Xu J; Ye Q
Hematology; 2017 Apr; 22(3):145-148. PubMed ID: 27875935
[TBL] [Abstract][Full Text] [Related]
14. Novel head-to-head gene fusion of MLL with ZC3H13 in a JAK2 V617F-positive patient with essential thrombocythemia without blast cells.
Duhoux FP; Ameye G; Lambert C; Herman M; Iossifidis S; Constantinescu SN; Libouton JM; Demoulin JB; Poirel HA
Leuk Res; 2012 Jan; 36(1):e27-30. PubMed ID: 21962339
[No Abstract] [Full Text] [Related]
15. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
[TBL] [Abstract][Full Text] [Related]
16. Myeloid sarcoma in essential thrombocythemia that transformed into acute myeloid leukemia.
Shikata H; Matumoto T; Teraoka H; Kaneko M; Nakanishi M; Yoshino T
Int J Hematol; 2009 Mar; 89(2):214-217. PubMed ID: 19172381
[TBL] [Abstract][Full Text] [Related]
17. Philadelphia-positive acute lymphoblastic leukemia in a case of MPL p.(W515L) variant essential thrombocythemia: case report and literature review.
Ma J; Chen S; Huang Y; Zi J; Ma J; Ge Z
Platelets; 2022 Aug; 33(6):945-950. PubMed ID: 34895021
[TBL] [Abstract][Full Text] [Related]
18. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
19. Genotype-phenotype interactions in the myeloproliferative neoplasms.
Godfrey AL; Green AR
Hematol Oncol Clin North Am; 2012 Oct; 26(5):993-1015. PubMed ID: 23009934
[TBL] [Abstract][Full Text] [Related]
20. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
